Mianserin and trazodone significantly attenuate the intensity of opioid withdrawal symptoms in mice

Addiction Biology

Volumn 8, Issue 1, 2003, Pages 107-114

  Schreiber, S ^a   Backer, M M ^b   Herman, I ^c   Shamir, D ^c   Rigai, T ^b   Bar Hamburger, R ^d   Pick, Chaim G ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Jaffa Ctr Treatm Drug Dependent P   (Israel)

^d Israel Anti Drug Authority   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

MIANSERIN; MORPHINE; NALOXONE; OPIATE; TRAZODONE;

ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; DETOXIFICATION; DRUG DEPENDENCE; MALE; MORPHINE ADDICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAIL FLICK TEST; WITHDRAWAL SYNDROME;

ADRENERGIC ALPHA-ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; DISEASE MODELS, ANIMAL; MIANSERIN; MICE; MORPHINE DEPENDENCE; SUBSTANCE WITHDRAWAL SYNDROME; TRAZODONE;

EID: 0037361270     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jerome H, Jaffe JH, Jaffe AB. Opioid-related disorders In: Sadock BJ, Kaplan HI & Sadock VA, editors. Kaplan & Sadock's Comprehensive textbook of psychiatry. New York: Lippincott Williams & Wilkins, 2000, pp. 842-63.
2. Brewer C. Combining pharmacological antagonists and behavioral psychotherapy in treating addictions. Why it is effective but unpopular Br J Psychiatry 1990;157:34-40.
3. Schreiber S, Backer MM, Kaufman J, Rigai T, Pick CG. Interaction between the tetracyclic antidepressant mianserin HCl and opioid receptors Eur Neuropsychopharmacol 1998;8:297-302.
4. Schreiber S, Backer MM, Pick CG. The antinociceptive effect of trazodone in mice is mediated through both μ-opioid and serotonergic mechanisms Behav Brain Res 2000;114:51-6.
5. Schreiber S, Herman I, Shamir D, Bar-Hamburger R, Pick CG. (submitted) The effect of mianserin and trazodone on the intensity of opioid withdrawal symptoms during detoxification programme - a double blind, placebo controlled study (submitted to J Nervous Mental Disease).
6. Tsuji M, Takeda H, Matsumiya T, et al. A novel μ-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice Life Sci 2000;66: PL353-8.
7. Guo GW, He Y, Jin WQ, Zou Y, Zhu YC, Chi ZQ. Comparison of physical dependence of ohmefentanyl stereoisomers in mice Life Sci 2000;67:113-20.
8. Langerman L, Steingart RA, Margolis A, Yanai L. Method of reducing the opioid withdrawal intensity using progressively increasing doses of naloxone J Pharmacol Toxicol Methods 1999;42:115-19.
9. Wang Z, Bilsky EJ, Wang D, Porreca F, Sadee W. 3-Isobutyl-1-methylxanthine inhibits basal m-opioid receptor phosphorylation and reverses acute morphine tolerance and dependence in mice Eur J Pharmacol 1999;371:1-9.
10. Belozertseva I, Zvartau E, Bespalov A. Behavioral effects of MK 801 in morphine-dependent and not dependent mice Life Sci 1996;58:, PL55-61.
11. Hamdy MM, Mamiya T, Noda Y, et al. A selective phosphodiesterase IV inhibitor, rolipram blocks both withdrawal behavioral manifestations, and c-Fos protein expression in morphine dependent mice Behav Brain Res 2001;118:85-93.
12. Schreiber S, Backer MM, Pick CG. The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms Neurosci Lett 1999;273:85-8.
13. Tierney C, Naduad D, Koenig-Berard E, Stinus L. Effects of two alpha2 agonists, rilmenidine and clonidine, on the morphine withdrawal syndrome and their potential addictive properties in rats Am J Cardiol 1988;61:35-8.
14. Tanganelli S, Antonelli T, Morari M, Bianchi C, Beani L. Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs Neurosci Lett 1991;122:270-2.
15. Frances B, Gout R, Cross J, Zajac J M. Effects of ibogaine on naloxone-precipitated withdrawal in morphine-dependent mice Fund Clin Pharmacol 1992;6:327-32.
16. Kimes AS, Vaupel DB, London ED. Attenuation of some signs of opioid withdrawal by inhibitors of nitric oxide synthase Psychopharmacology 1993;112:521-4.
17. Rafieian-Kopaei M, Gray AM, Spencer PS, Sewell RD. Contrasting actions of acute or chronic paroxetine and fluvoxamine on morphine withdrawal-induced place conditioning Eur J Pharmacol 1995;275:185-9.
18. Cervo L, Ballabio M, Caccia S, Samanin R. Blockade by trazodone of naloxone-precipitated jumping on morphine-dependent rats: correlation with brain levels of m-chlorophenylpiperazine J Pharm Pharmacol 1981;33:813-14.
19. Neal BS, Sparber SB. Mianserin attenuates naloxone-precipitated withdrawal signs in rats acutely or chronically dependent upon morphine J Pharmacol Exp Ther 1986;236:157-65.
20. Valeri P, Pimpinella G, Morrone LA, Romanelli L. Antinociceptive effects of trazodone and m-chlorophenylpiperazine (mCPP) in mice: interaction with morphine Gen Pharmacol 1991;22:127-31.
21. Schreiber S, Bleich A, Pick CG. Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects - a possible opioid involvement in severe depression? J Mol Neurosci 2002;18:143-9.
22. Pick CG, Peter Y, Schreiber S, Weizman R. Pharmacological Characterization of buprenorphine, a mixed agonist - antagonist with kappa3 analgesia Brain Res 1997;744:41-6.
23. Wolfe RM. Antidepressant withdrawal reactions Am Family Phys 1997;56:455-62.